DK1621077T3 - Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom - Google Patents

Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom

Info

Publication number
DK1621077T3
DK1621077T3 DK05077338T DK05077338T DK1621077T3 DK 1621077 T3 DK1621077 T3 DK 1621077T3 DK 05077338 T DK05077338 T DK 05077338T DK 05077338 T DK05077338 T DK 05077338T DK 1621077 T3 DK1621077 T3 DK 1621077T3
Authority
DK
Denmark
Prior art keywords
hodkin
lymphoma
arsenic trioxide
treatment
pharmaceutical compositions
Prior art date
Application number
DK05077338T
Other languages
English (en)
Inventor
Ralph M Ellison
Fred H Mermelstein
Original Assignee
Polarx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polarx Biopharmaceuticals Inc filed Critical Polarx Biopharmaceuticals Inc
Application granted granted Critical
Publication of DK1621077T3 publication Critical patent/DK1621077T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05077338T 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom DK1621077T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6237597P 1997-10-15 1997-10-15
PCT/US1998/021782 WO1999018798A1 (en) 1997-10-15 1998-10-15 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

Publications (1)

Publication Number Publication Date
DK1621077T3 true DK1621077T3 (da) 2009-01-26

Family

ID=22042073

Family Applications (4)

Application Number Title Priority Date Filing Date
DK03019628T DK1391206T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxyd til behandling af ikke-Hodgkins lymfom
DK03019594T DK1378240T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
DK08016665.5T DK2018858T3 (da) 1997-10-15 1998-10-15 Sammensætninger og fremgangsmåder til behandlingen af primære og metastatiske neoplastiske sygdomme ved anvendelse af arsentrioxid
DK05077338T DK1621077T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK03019628T DK1391206T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxyd til behandling af ikke-Hodgkins lymfom
DK03019594T DK1378240T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
DK08016665.5T DK2018858T3 (da) 1997-10-15 1998-10-15 Sammensætninger og fremgangsmåder til behandlingen af primære og metastatiske neoplastiske sygdomme ved anvendelse af arsentrioxid

Country Status (21)

Country Link
US (9) US6875451B2 (da)
EP (9) EP1378241A1 (da)
JP (1) JP2001519366A (da)
KR (1) KR20010015755A (da)
CN (1) CN1282218A (da)
AT (4) ATE407683T1 (da)
AU (1) AU751932B2 (da)
BR (1) BR9813085A (da)
CA (1) CA2307208A1 (da)
CY (4) CY1108363T1 (da)
DE (4) DE69839682D1 (da)
DK (4) DK1391206T3 (da)
ES (4) ES2312701T3 (da)
HK (3) HK1061199A1 (da)
IL (1) IL135620A0 (da)
NO (1) NO20001977L (da)
NZ (1) NZ503973A (da)
PL (1) PL339909A1 (da)
PT (4) PT2018858E (da)
TR (1) TR200001959T2 (da)
WO (1) WO1999018798A1 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964557B1 (en) * 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
DE10196619D2 (en) * 2001-07-05 2004-05-06 Hans-Werner Luedke Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
KR100492940B1 (ko) * 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
ES2330519T3 (es) 2002-11-07 2009-12-11 Newsouth Innovations Pty Limited Inducion de la transicion de permeabilidad mitocondrial.
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005062810A2 (en) * 2003-12-18 2005-07-14 Mediscovery, Llc Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
BRPI0508382A (pt) * 2004-03-01 2007-07-31 Peptimmune Inc métodos e composições para tratamento de doenças auto-imunes
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
US20050208149A1 (en) * 2004-03-18 2005-09-22 Tty Biopharm Limited Company Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US20060003966A1 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
WO2006024489A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
WO2006102439A2 (en) 2005-03-23 2006-09-28 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US7968738B2 (en) 2005-07-29 2011-06-28 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
US8784899B2 (en) * 2005-10-04 2014-07-22 Samuel Waxman Cancer Research Foundation Compositions and methods for cancer treatment
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
ITMI20060480A1 (it) * 2006-03-16 2007-09-17 Solvay Solexis Spa Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
EP2069371B1 (en) 2006-11-01 2013-03-13 NewSouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
CN103788108B (zh) 2007-02-06 2017-04-12 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
CA2718472A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
WO2009045440A1 (en) 2007-10-01 2009-04-09 Lixte Biotechnology Holdings, Inc. Hdac inhibitors
ES2392737T3 (es) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Terapia combinada con compuestos arsenicales orgánicos
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014141A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
AU2009277086B2 (en) * 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
DK3388111T3 (da) 2008-08-20 2021-12-06 Solasia Pharma K K Organoarsenforbindelse til behandlingen af kræft
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
TR201905548T4 (tr) * 2009-09-10 2019-05-21 Kominox Inc Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi.
IN2012DN02195A (da) * 2009-09-18 2015-08-21 Kominox Inc
US20120015023A1 (en) * 2010-04-15 2012-01-19 Antimisiaris Sophia G Treatment of tumors prostate with arsonoliposomes
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
AU2014251087B2 (en) 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
MX2019006107A (es) 2016-12-01 2019-08-21 Eupharma Pty Ltd Composiciones de arsenico.
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
WO2018209343A1 (en) * 2017-05-12 2018-11-15 Rajur Sharanappa Basappa Novel methods, compounds, and compositions: small molecule anticancer agents
WO2019234112A1 (en) 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
CN114028425A (zh) * 2021-09-24 2022-02-11 上海交通大学医学院附属新华医院 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用
CN115634287A (zh) * 2022-09-30 2023-01-24 苏州系统医学研究所 一种基于砷化合物的肿瘤疫苗及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132275A (en) 1872-10-15 Improvement in medical compounds
US232807A (en) 1880-10-05 Herbert e
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4599305A (en) * 1984-07-16 1986-07-08 The Regents Of The University Of California Method and composition for detection of human chronic myelogenous leukemia
NL8502929A (nl) * 1985-10-25 1987-05-18 Tno Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
DK0651636T3 (da) 1992-07-24 2003-01-27 Univ Johns Hopkins Kemoterapi for cancer
FR2699820B3 (fr) * 1992-12-24 1995-03-10 Eric Pichot Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques.
DE4317331A1 (de) * 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
US5889048A (en) 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) * 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
US5748699A (en) * 1995-10-06 1998-05-05 Smith; Donald O. Apparatus for applying X-rays to an interior surface of a body cavity
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
EP1964557B1 (en) * 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
MXPA05003161A (es) * 2002-09-24 2005-09-12 Novartis Ag Uso de derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm

Also Published As

Publication number Publication date
JP2001519366A (ja) 2001-10-23
PT1378240E (pt) 2008-11-14
EP1621077A1 (en) 2006-02-01
HK1061198A1 (en) 2004-09-10
US7163703B2 (en) 2007-01-16
EP1621077B1 (en) 2008-09-24
PT1391206E (pt) 2008-08-13
BR9813085A (pt) 2000-08-22
EP1466607A1 (en) 2004-10-13
DE69840006D1 (de) 2008-10-23
PT1621077E (pt) 2008-11-04
US6875451B2 (en) 2005-04-05
DE69839682D1 (de) 2008-08-14
NO20001977L (no) 2000-06-13
HK1061199A1 (en) 2004-09-10
ES2312701T3 (es) 2009-03-01
EP1378241A1 (en) 2004-01-07
CA2307208A1 (en) 1999-04-22
ATE409043T1 (de) 2008-10-15
US20020183385A1 (en) 2002-12-05
US7132116B2 (en) 2006-11-07
US20050191367A1 (en) 2005-09-01
AU1089399A (en) 1999-05-03
US7179493B2 (en) 2007-02-20
US20040115283A1 (en) 2004-06-17
EP1378240A3 (en) 2004-01-14
DK1378240T3 (da) 2008-12-08
PL339909A1 (en) 2001-01-15
EP1391206A1 (en) 2004-02-25
US20040197421A1 (en) 2004-10-07
EP1022951A4 (en) 2002-06-19
EP1022951A1 (en) 2000-08-02
ATE399560T1 (de) 2008-07-15
EP2018858A1 (en) 2009-01-28
US20040197420A1 (en) 2004-10-07
CY1110057T1 (el) 2015-01-14
DE69840057D1 (de) 2008-11-06
EP1378240A2 (en) 2004-01-07
ES2313201T3 (es) 2009-03-01
AU751932B2 (en) 2002-08-29
CY1108363T1 (el) 2014-02-12
EP1374875A3 (en) 2004-01-07
ATE493979T1 (de) 2011-01-15
CY1111379T1 (el) 2015-08-05
US20040047916A1 (en) 2004-03-11
EP1419778A1 (en) 2004-05-19
EP1374875A2 (en) 2004-01-02
ES2309258T3 (es) 2008-12-16
TR200001959T2 (tr) 2000-11-21
US7205001B2 (en) 2007-04-17
US20040161475A1 (en) 2004-08-19
HK1085886A1 (en) 2006-09-08
PT2018858E (pt) 2011-03-24
DK1391206T3 (da) 2008-09-01
DE69842094D1 (de) 2011-02-17
ATE407683T1 (de) 2008-09-15
IL135620A0 (en) 2001-05-20
US20040096518A1 (en) 2004-05-20
NO20001977D0 (no) 2000-04-14
ES2358624T3 (es) 2011-05-12
EP2018858B1 (en) 2011-01-05
DK2018858T3 (da) 2013-01-07
WO1999018798A1 (en) 1999-04-22
NZ503973A (en) 2001-09-28
CY1110055T1 (el) 2015-01-14
EP1378240B1 (en) 2008-09-10
CN1282218A (zh) 2001-01-31
US20050100611A1 (en) 2005-05-12
EP1391206B1 (en) 2008-07-02
KR20010015755A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
DK1621077T3 (da) Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom
DE69828436D1 (de) Radioaktive embolisierende zusammensetzungen
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
IL150767A (en) Benzophyrene compounds and their use in the manufacture of drugs for the treatment of estrogen-sensitive diseases such as endometrial cancer
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
ATE243692T1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
DE69823493D1 (de) Tetrahydropyridoverbindungen
ATE456377T1 (de) Behandlung des metastasierenden karzinoms der niere
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
EP0793499A4 (en) METHOD AND MEANS FOR REDUCING TUMOR DEVELOPMENT BY MEANS OF A COMBINATION OF A TAXAN COMPOUND AND A TELLUR AND / OR SELENIUM COMPOUND
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin